Amrit Ray

Amrit Ray

Director/Board Member at ULTRAGENYX PHARMACEUTICAL INC.

Net worth: 2 M $ as of 30/05/2026

53 year
Health Technology
Commercial Services
Consumer Services

Profile

Amrit Ray currently works at Ultragenyx Pharmaceutical, Inc., as Independent Director from 2022, Everylife Foundation for Rare Diseases, as Director, CorEvitas LLC, as Director from 2021, Fortrea Holdings, Inc., as Lead Independent Director from 2025, and The Hastings Center, as Director.
Dr. Ray also formerly worked at Johnson & Johnson, as Chief Medical Officer, Pfizer Inc., as Global President-Research & Development from 2017 to 2021, and Biohaven Pharmaceuticals, Inc., as Chief Patient Officer in 2022.
Dr. Ray received his undergraduate degree and doctorate degree from The University of Edinburgh and Masters Business Admin degree from Tuck School of Business at Dartmouth.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
09/06/2026 52,453 ( 0.06% ) 807 252 $ 30/05/2026
13/05/2026 31,116 ( 0.03% ) 744 917 $ 30/05/2026

Amrit Ray active positions

CompaniesPositionStart
ULTRAGENYX PHARMACEUTICAL INC. Director/Board Member 18/04/2022
FORTREA HOLDINGS INC. Director/Board Member 28/06/2023
Director/Board Member 02/08/2021
Director/Board Member -
Director/Board Member -

Former positions of Amrit Ray

CompaniesPositionEnd
Corporate Officer/Principal 30/11/2022
PFIZER INC. Chief Tech/Sci/R&D Officer 31/12/2020
JOHNSON & JOHNSON Chief Tech/Sci/R&D Officer -
See the detail of Amrit Ray's experience

Training of Amrit Ray

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

41

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Health Technology

Consumer Services

Commercial Services

Consumer Services

Commercial Services

Health Technology

Commercial Services

Commercial Services

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!